We would like to congratulate Lott et al1 for their interesting article regarding the potential value of acetylcholinesterase inhibitors for the treatment of dementia in people with Down syndrome (DS). Dementia is increasingly common in DS, with 25% to 35% of the DS population aged 50 to 60 years being affected2,3; however, research on therapeutic interventions for dementia in this group remains sparse.
Margallo-Lana ML, Ballard C, Morris C, Kay D, Tyrer S, Moore B. Cognitive Decline in Down Syndrome. Arch Neurol. 2003;60(7):1024. doi:10.1001/archneur.60.7.1024-a